Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

EU approves Sanofi and Regeneron’s dupilumab in eczema

Written by: | no-reply@reuters.com | Dated: Thursday, September 28th, 2017

 

PARIS (Reuters) – The European Commission approved Regeneron Pharmaceuticals’ and Sanofi’s key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said on Thursday.

The move comes after the U.S Food and Drug Administration (FDA) regulator had also approved the injectable antibody drug in March. The product is sold as Dupixent.

Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching.

A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are believed to be major drivers of the disease.

Sanofi plans to submit an application to the FDA for a use of dupilumab in asthma by the end of the year and hinted recently at a possible use of the drug in nasal polyps.

Analysts on average expect Dupixent to reach annual sales of 4.7 billion euros ($5.53 billion) by 2023, according to Thomson Reuters data.

Shares of Regeneron and Sanofi slid earlier this month after late-stage trial data for dupilumab in asthma fell short of investor expectations. Analysts said the data appeared less impressive than the drug’s mid-stage data.

Investors had also expressed disappointment with the sales take-up of Dupixent when Sanofi published its second quarter-results in July, although but Sanofi expressed confidence that the drug would sell well.

 

Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta

 

Reuters source:

http://www.reuters.com/article/us-sanofi-regeneron/eu-approves-sanofi-and-regenerons-dupilumab-in-eczema-idUSKCN1C313B

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation